ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
CORE Biomedicine closed a $21 million Series A funding round. The investment will support the company's development of precision medicine technologies for treating neurological disorders.
Tap to vote and see what everyone thinks.
Summary by ByteBrief